Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $49.47B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2026 · Mkt cap
Decision snapshot: XYZ stock price vs ROIV: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ROIV's multiple
Needs ROIV P/E.
Implied fair value · at XYZ's multiple
Needs EPS (TTM) is negative, XYZ P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: XYZ FY 2025 (ended Dec 31, 2025) · ROIV FY 2026 (ended Mar 31, 2026). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 74% equity / 26% debt · EV / Revenue 2.48x · EV / EBITDA 26.61x
Capital structure 98% equity / 2% debt · EV / Revenue 2584.97x
XYZ carries the larger enterprise value at $59.88B against $21.35B; XYZ trades on the lower EV / Revenue multiple (2.48x vs 2584.97x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Block, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
ROIVANT SCIENCES LTD. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.76x
0.09x
Net debt / EBITDA
Leverage against operating earnings
4.63x
24.52x
Cash and equivalents
Liquid reserves on the balance sheet
$6.56B
$4.29B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
INTUIT INC.
XYZ vs INTU
PayPal Holdings, Inc.
XYZ vs PYPL
Shift4 Payments, Inc.
XYZ vs FOUR
FISERV INC
XYZ vs FI
GLOBAL PAYMENTS INC
XYZ vs GPN
WEX Inc.
XYZ vs WEX
Revolution Medicines, Inc.
XYZ vs RVMD
INCYTE CORP
XYZ vs INCY
Sarepta Therapeutics, Inc.
XYZ vs SRPT
EXELIXIS, INC.
XYZ vs EXEL
VERTEX PHARMACEUTICALS INC / MA
XYZ vs VRTX
$16.98B
$412.94M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
